When was Terns Pharmaceutical founded?

Terns Pharmaceutical was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Terns Pharmaceutical located?

Terns Pharmaceutical is headquartered in San Mateo, United States. It is registered at San Mateo (United States).

Who is the current CEO of Terns Pharmaceutical?

Weidong Zhong of Terns Pharmaceutical.

How many employees does Terns Pharmaceutical have?

As of Apr 30, 2026, the latest employee count at Terns Pharmaceutical is 68.

Is Terns Pharmaceutical a funded company?

Terns Pharmaceutical is a funded company, having raised a total of $208M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 2018.

When was the latest funding round of Terns Pharmaceutical?

Terns Pharmaceutical's latest funding was a $***** Series C round on Jan 05, 2021, with participation from 6 investors.

What is the annual revenue of Terns Pharmaceutical?

Annual revenue of Terns Pharmaceutical is $1M as on Dec 31, 2021.

Where does Terns Pharmaceutical rank among its competitors?

Terns Pharmaceutical ranks 13th amongst 146 active competitors, of which 48 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Enyo Pharma, which secured $6.87M in Jun, 2025.

Who are the top competitors of Terns Pharmaceutical?

Terns Pharmaceutical's top competitors include Forge Biologics, Krystal Biotech and Nimbus Therapeutics. Among them, Enyo Pharma secured the most recent funding round in June, 2025.

Terns Pharmaceutical - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapies for treating liver disease and cancer. The lead candidate TERN 101 is a Farnesoid X Receptor agonist (nuclear receptor expressed in high amount), other candidates are TERN 201, TERN 501, and GLP-1R-agonist. These are used for treating Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD).

Website: ternspharma.com
Social
Email ID: *****@ternspharma.com
Registered Address: San Mateo (United States)

Key Metrics

Founded Year

2017

Location

San Mateo, United States

Stage

Acquired

Total Funding

$208M in 3 rounds

Latest Funding Round

Series C, Jan 05, 2021, $*****

Investors

Orbimed & 7 more

Ranked

13^th among 146 active competitors

Annual Revenue

$1M as on Dec 31, 2021

Employee Count

68 as on Apr 30, 2026

Similar Companies

Forge Biologics & 95 more

Exit Details

Acquired by Merck (Mar 25, 2026)

View Terns Pharmaceutical's full profile

Terns Pharmaceutical is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TERNS PHARMACEUTICALS, INC. CIN: 001-39926 , United States, Active	Dec 31, 2016	$1M (As on Dec 31, 2021)	46 (As on Dec 31, 2022)	-

Terns Pharmaceutical got acquired by Merck on Mar 25, 2026.

Click here to take a look at Terns Pharmaceutical's acquisition in detail

Terns Pharmaceutical has raised a total funding of $208M over 3 rounds. Its first funding round was on Apr 2018. Its latest funding round was a Series C round on Jan 05, 2021 for $*****. 6 investors participated in its latest round. Terns Pharmaceutical has 8 institutional investors.

Here is the list of recent funding rounds of Terns Pharmaceutical:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 05, 2021	9439423	Series C	8139236	4298259	7556667	1251939
Oct 30, 2018	2102858	Series B	4436036	6249836	1187208	Decheng Capital & 1 more
Apr 2018	7971514	Series A	9866248	5193739	Lilly Asia Ventures	4556128

Access funding benchmarks and valuations. Sign up today!

View details of Terns Pharmaceutical's funding rounds and investors

The founders of Terns Pharmaceutical is Weidong Zhong.

Here are the details of Terns Pharmaceutical's key team members:

Weidong Zhong: Founder & CEO of Terns Pharmaceutical.

View details of Terns Pharmaceutical's Founder profiles and Board Members

Terns Pharmaceutical's employee count trend

Terns Pharmaceutical has 68 employees as of Apr 26. Here is Terns Pharmaceutical's employee count trend over the years:

Employee count trend for Terns Pharmaceutical

Uncover Terns Pharmaceutical's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Terns Pharmaceutical include Forge Biologics, Krystal Biotech and Nimbus Therapeutics. Here is the list of Top 10 competitors of Terns Pharmaceutical, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
2nd	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	69/100
3rd	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
4th	Kiniksa Pharmaceuticals 2015, Lexington (United States), Public	Developer of therapeutics for multiple diseases treatment	$320M	Fidelity Investments, Sofinnova Investments ... & 8 others	67/100
5th	Intercept Pharmaceuticals 2002, New York City (United States), Acquired	Developer of therapeutics to treat progressive non-viral liver diseases	$121M	Orbimed, JAFCO Group & 6 others	66/100
6th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Mayfield & 34 others	65/100
7th	Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired	Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis	$38.4M	Avoro Capital, Bay City Capital & 1 others	64/100
8th	Drug Farm 2015, Shanghai (China), Series C	Developer of a novel treatment for metabolic diseases	$83M	Zhejiang Private Enterprise United Investment, BioVeda China Fund ... & 7 others	63/100
9th	Innovent Bio 2011, Suzhou (China), Public	Developer of antibody therapeutics for multiple diseases	$535M	Eight Roads Ventures, Lilly Asia Ventures ... & 24 others	62/100
10th	Enyo Pharma 2014, Lyon (France), Series C	Developer of therapeutics for diseases with impaired kidney function	$120M	Orbimed, Morningside & 9 others	62/100
13th	Terns Pharmaceutical 2017, San Mateo (United States), Acquired	Developer of therapies for treating liver disease and cancer	$208M	Deerfield, Vivo Capital & 6 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Terns Pharmaceutical's competitors? Click here to see the top ones

Terns Pharmaceutical has made no investments or acquisitions yet.

Here is the latest report on Terns Pharmaceutical's sector:

Free

Gastroenterology - Sector Report

Edition: November, 2025 (69 Pages)

View all reports related to Terns Pharmaceutical

Media has covered Terns Pharmaceutical for a total of 21 events in the last 1 year, 11 of them have been about company updates and 1 about people movement.